Last reviewed · How we verify
Lanoxin (digoxin)
Digoxin (Lanoxin) is a cardiac glycoside derived from foxglove, used since the 18th century. It remains useful for heart failure and atrial fibrillation rate control. Narrow therapeutic index requires drug level monitoring. Available generically.
At a glance
| Generic name | digoxin |
|---|---|
| Also known as | Lanoxin, Digitek |
| Sponsor | Generic (originally Burroughs Wellcome/GSK) |
| Drug class | Cardiac Glycoside [EPC] |
| Target | Nuclear receptor ROR-gamma, Signal transducer and activator of transcription 3, Potassium voltage-gated channel subfamily H member 2 |
| Modality | Small molecule (natural product) |
| Therapeutic area | Metabolic |
| Phase | FDA-approved |
| First approval | 1954-01-01 (United States) |
Approved indications
- Atrial fibrillation
- Chronic heart failure
- Poisoning by digitalis glycoside
Common side effects
- Nausea
- Vomiting
- Headache
- Weakness
- Dizziness
- Apathy
- Confusion
- Mental disturbances
- Anxiety
- Depression
- Delirium
- Hallucination
Serious adverse events
- Cardiac arrhythmias
- Digoxin toxicity
- Cardiac toxicity
- Intestinal ischemia
- Hemorrhagic necrosis of the intestines
- Thrombocytopenia
Key clinical trials
- Optimising Pacing Therapy, Integrated Medical Therapy, and Catheter AbLation for Atrial Fibrillation in Heart Failure Trial (Phase 4)
- A Phase 1, Open-Label Study to Evaluate the Effect of AT-527 on the Pharmacokinetics of Digoxin in Healthy Adult Subjects (Phase 1)
- A Phase 1, Open-Label, Single-Sequence Crossover Study Assessing the Effect of Tivantinib (ARQ 197) on the Pharmacokinetics of Omeprazole/S-Warfarin/Caffeine/Midazolam and Digoxin in Cancer Subjects (Phase 1)
- The Effectiveness of Autologous Mono Nuclear Cells in the Treatment of Dilated Cardiomyopathy in Children (NA)
- A Phase 1, Open-Label, Two-Part Study to Evaluate the Effect of a Single Oral Dose of Bemnifosbuvir/Ruzasvir Fixed Dose Combination on the Pharmacokinetics of Digoxin and Rosuvastatin in Healthy Subje (Phase 1)
- A Prospective Phase Ib/IIa, Active-controlled, Randomized, Open-label Study to Evaluate the Safety, Tolerability, Extended Early Bactericidal Activity and Pharmacokinetics of Multiple Oral Doses of BT (Phase 1)
- Assessment of the Efficacy and Safety of a Short Term Treatment With Digoxin on Patients With Acute Heart Failure Syndromes. A Randomized Controlled Trial. (Phase 3)
- Comparison of Brain Perfusion in Rhythm Control and Rate Control of Persistent Atrial Fibrillation: Prospective Randomized Trial (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |